Thromb Haemost 2008; 99(01): 174-181
DOI: 10.1160/TH07-08-0503
Cardiovascular Biology and Cell Signalling
Schattauer GmbH

Impact of cytochrome P450 3A4-metabolized statins on the antiplatelet effect of a 600-mg loading dose clopidogrel and on clinical outcome in patients undergoing elective coronary stent placement

Dietmar Trenk
1   Herz-Zentrum Bad Krozingen, Bad Krozingen, Germany
,
Willibald Hochholzer
1   Herz-Zentrum Bad Krozingen, Bad Krozingen, Germany
,
Devine Frundi
1   Herz-Zentrum Bad Krozingen, Bad Krozingen, Germany
,
Christian Stratz
1   Herz-Zentrum Bad Krozingen, Bad Krozingen, Germany
,
Christian M Valina
1   Herz-Zentrum Bad Krozingen, Bad Krozingen, Germany
,
Hans-Peter Bestehorn
1   Herz-Zentrum Bad Krozingen, Bad Krozingen, Germany
,
Heinz Joachim Büttner
1   Herz-Zentrum Bad Krozingen, Bad Krozingen, Germany
,
Franz-Josef Neumann
1   Herz-Zentrum Bad Krozingen, Bad Krozingen, Germany
› Author Affiliations
Further Information

Correspondence to:

Dr. Dietmar Trenk
Herz-Zentrum Bad Krozingen
Suedring 15, 79189 Bad Krozingen, Germany
Phone: +49 7633 402 2480   
Fax: +49 7633 402 2489   

Publication History

Received: 08 October 2007

Accepted after major revision: 10 October 2007

Publication Date:
24 November 2017 (online)

 

Summary

Early studies suggested interactions between statins and clopidogrel. Based on the outcome and platelet data, there is now huge evidence of no interactions between statins and 75 to 300 mg clopidogrel; however, data with 600-mg loading are lacking. In a pre-specified analysis of the EXCELSIOR cohort, we investigated the interaction between statins, especially cytochrome P4503A4-metabolized atorvastatin and simvastatin, and the antiplatelet effects of a 600-mg loading dose of clopidogrel. We analyzed 1,395 patients scheduled for coronary angiography (CA). Patients received clopidogrel 600 mg at least two hours before CA and 75 mg daily thereafter in case of percutaneous coronary intervention (PCI). Statin medication on admission was continued unaltered until discharge. Platelet function was assessed by optical aggregometry and flow cytometry of adenosine diphosphate (ADP)-stimulated surface expression of CD62P, CD63 and PAC-1 before clopidogrel and immediately before CA. Residual platelet aggregation (RPA) after addition of ADP 5 μM was similar irrespective of statin treatment at baseline (p=0.968). RPA at CA was 46.2 ± 16.8% in patients without statin (n=682), 45.5 ± 17.0% in patients with atorvastatin (n=255), 45.8 ± 16.3% with simvastatin (n=335), 47.3 ± 14.9% with fluvastatin (n=42) and 45.9 ± 16.2% with pravastatin (n=81; p=0.962). Consistent results were obtained by flow cytometry. In patients with PCI (n=553), the one-year incidence of death, myocardial infarction and target lesion reintervention did not differ between cohorts stratified according to statin co-medication (p=0.645).Thus, peri-interventional atorvastatin and simvastatin had no effect on the antiplatelet activity of a loading dose of clopidogrel 600 mg and did not affect clinical outcome after PCI.


 



Correspondence to:

Dr. Dietmar Trenk
Herz-Zentrum Bad Krozingen
Suedring 15, 79189 Bad Krozingen, Germany
Phone: +49 7633 402 2480   
Fax: +49 7633 402 2489